Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model.
Hadad
Sirwan M
SM
Appleyard
Virginia
V
Thompson
Alastair M
AM
D055372:AMP-Activated Protein Kinases / Q000378:metabolism*; D000818:Animals; D001943:Breast Neoplasms / Q000098:blood supply* / Q000188:drug therapy* / Q000473:pathology; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D004789:Enzyme Activation / Q000187:drug effects; D047628:Estrogen Receptor alpha / Q000172:deficiency*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008545:Melanoma; D008687:Metformin / Q000627:therapeutic use*; D051379:Mice; D009389:Neovascularization, Pathologic; D010641:Phenotype
D047628:Estrogen Receptor alpha; D007004:Hypoglycemic Agents; D008687:Metformin; D055372:AMP-Activated Protein Kinases